


Oncotest, Debiopharm identify biomarker candidates

25 April 2013 | News | By BioSpectrum Bureau



Singapore: Germany-based Oncotest and Debiopharm, a Swiss-based global biopharmaceutical group, have completed first biomarker projects at Oncotest.

The pharmacological data was generated with Debiopharm's investigational compound in Oncotest's 3D assay system for patient-derived xenografts and correlated with the extensive Oncotest's genomic and transcriptomic data. The collaboration resulted in the identification of several predictive biomarkers candidates including a gene signature.

"We are enthusiastic to work with Debiopharm on these projects and are looking forward to continue and expand our collaboration. I am convinced that the concept of deriving predictive biomarkers for new drugs already in a preclinical setting will make an impact. Ultimately, it has a significant potential to lower the attrition rates in clinical trials. Today, with our new biomarker department and the characterization data available for our tumor models, Oncotest is ideally positioned in this area." said Prof Heiner Fiebig, founder and CEO, Oncotest.

Dr Hiroaki Tanaka, personalized medicine director, Debiopharm, added that, "Reliable preclinical models are key success factors in drug development. We believe that technologies based on the direct use of patient tumors have a game-changer potential in translational research in oncology. We are happy to collaborate with Oncotest, a pioneer and a leader in the area, and we are looking forward to extending our partnership even further towards the achievement of personalized medicine."